Following the success of our HTA conference at UEGW last October, EFCCA is pleased to share the final report from a two-round consultation with stakeholders and experts.

We are excited to invite you to the upcoming EFCCA Conference "What do IBD patients find important in their treatment? -  Results from a global Patient
Preference survey” that will take place on 20 February 2025 at the ECCO Congress in Berlin.

Registrations are open! This non-invasive technique is emerging as a valuable tool for diagnosis, treatment, and disease monitoring in IBD patients. Don’t miss this opportunity to learn and share your views!

Aiming to revolutionise personalised prevention and early treatment in chronic inflammatory diseases (CIDs), the PerPrev-CID project focuses on advancing risk prediction, early detection of disease progression, and innovative preventive approaches in rheumatoid arthritis (RA) and Inflammatory Bowel Disease (IBD).

Registrations are open for the 1st GlycanTrigger Patients Symposium, an important event we are co-organising together with the Portuguese Society for Innovation (SPI), focused on collaborative discussions around strategies for predicting and preventing IBD.

We’re excited to present the latest issue of the EFCCA Magazine, now with a refreshed design! Inside, you’ll find an exclusive interview with Professor James Lee, who shares insights on his groundbreaking research into the causes of Inflammatory Bowel Disease (IBD).

EFCCA is excited to introduce a series of webinars, workshops and initiatives to be launched after the summer break.

We are pleased to announce the release of two significant reports that highlight our continuous efforts and achievements in advocating for improved IBD care and quality of life worldwide.

From 7 to 9 June 2024, Brussels hosted the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) General Assembly, representing a significant event for our organisation.